{"id":2858,"date":"2026-08-25T10:17:29","date_gmt":"2026-08-25T10:17:29","guid":{"rendered":"https:\/\/officialcorepeptides.brandloom.net\/it\/?post_type=product&p=2858"},"modified":"2026-08-25T10:17:30","modified_gmt":"2026-08-25T10:17:30","slug":"buy-hexarelin-5mg-in-switzerland","status":"publish","type":"product","link":"https:\/\/officialcorepeptides.ch\/it\/product\/buy-hexarelin-5mg-in-switzerland\/","title":{"rendered":"Hexarelin (5MG)"},"content":{"rendered":"

What Is Hexarelin and Why Buy It for Research?<\/strong><\/h2>\n

Buy Hexarelin 5mg in Switzerland for research into growth hormone axis signaling, ghrelin receptor pharmacology, and cardioprotective pathways. Specifically, Hexarelin (also known as Examorelin) is a synthetic hexapeptide composed of six amino acids with the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH\u2082. It is a member of the growth hormone-releasing peptide (GHRP) family and acts as a potent agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a), also known as the ghrelin receptor.<\/p>\n

Hexarelin is structurally similar to GHRP-6 but contains a key modification: a 2-methyl group on the tryptophan residue at position 2 (D-2-methyl-Trp), which enhances its potency and stability. This modification, along with the D-amino acid residues, contributes to Hexarelin’s resistance to proteolytic degradation and its potent biological activity. Hexarelin has a molecular weight of 887.0 g\/mol and the molecular formula C\u2084\u2087H\u2085\u2088N\u2081\u2082O\u2086.<\/p>\n

In scientific research, Hexarelin serves as a molecular tool for studying GH secretion pathways, ghrelin receptor signaling, and CD36-mediated cardioprotective mechanisms. Furthermore, Core Peptides supplies Hexarelin as a lyophilized powder in a 5mg format exclusively for laboratory use. Therefore, researchers seeking to source this compound for their work will find it readily available when they buy Hexarelin 5mg in Switzerland.<\/p>\n

Hexarelin Research Overview: Buy Hexarelin 5mg in Switzerland for GHS-R1a Studies<\/strong><\/h2>\n

Centrally, research into Hexarelin has focused on its function as a potent agonist of the ghrelin receptor (GHS-R1a). Hexarelin mimics the action of the endogenous ligand ghrelin, binding to the GHS-R1a with high affinity. This binding event initiates a conformational change in the receptor, a G-protein-coupled receptor (GPCR), leading to the activation of downstream signaling pathways. Hexarelin acts at both hypothalamic and pituitary sites to powerfully stimulate the release of growth hormone (GH).<\/p>\n

The primary signaling pathway involves the coupling of activated GHS-R1a to the G\u03b1q\/11 subunit of the heterotrimeric G protein. This activation stimulates phospholipase C (PLC), which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into two key second messengers: inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers the release of stored calcium (Ca\u00b2\u207a) from the endoplasmic reticulum, and this sharp increase in intracellular calcium is critical for the exocytosis of growth hormone-containing vesicles from somatotroph cells in the anterior pituitary. Additionally, DAG activates protein kinase C (PKC), contributing to downstream cellular responses. This canonical pathway is central to the potent secretagogue effect of Hexarelin on growth hormone.<\/p>\n

A distinguishing feature of Hexarelin is its unique binding to the scavenger receptor CD36, which mediates many of its GH-independent cardioprotective effects including anti-atherosclerotic and anti-ischemic activity. Accordingly, researchers who buy Hexarelin 5mg in Switzerland from Core Peptides can support their investigations into GHS-R1a signaling, GH secretion, CD36-mediated pathways, and cardioprotective mechanisms.<\/p>\n

How Does Hexarelin Work in Research?<\/strong><\/h2>\n

Mechanistically, Hexarelin’s proposed action involves functioning as a ghrelin receptor agonist that activates GHS-R1a to stimulate GH release through multiple signaling pathways, with additional CD36-mediated effects. The peptide operates through several interconnected mechanisms.<\/p>\n

GHS-R1a Receptor Activation<\/strong><\/h3>\n

Hexarelin binds to and activates the growth hormone secretagogue receptor type 1a (GHS-R1a), a G-protein coupled receptor (GPCR) expressed on pituitary somatotrophs and in hypothalamic neurons. Hexarelin is chemically more stable and functionally more potent when compared with ghrelin[reference:0]. In CHO cells transfected with the GHS-R1a, Hexarelin stimulated calcium levels in a concentration-dependent fashion<\/p>\n

Intracellular Signaling Cascade<\/strong><\/h3>\n

The primary signaling pathway involves the coupling of activated GHS-R1a to the G\u03b1q\/11 subunit of the heterotrimeric G protein. This activation stimulates phospholipase C (PLC), which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers the release of stored calcium (Ca\u00b2\u207a) from the endoplasmic reticulum, and the resulting sharp increase in intracellular calcium is critical for the exocytosis of growth hormone-containing vesicles. Additionally, DAG activates protein kinase C (PKC), which contributes to downstream cellular responses. Hexarelin’s biological effects are mediated by a complex and interconnected network of signaling pathways, including the PLC\/PKC, MAPK\/ERK, and PI3K\/Akt cascades through both GHS-R1a and CD36<\/p>\n

Growth Hormone Release<\/strong><\/h3>\n

Hexarelin stimulates potent release of endogenous growth hormone from the pituitary gland. The peptide is a potent pituitary GH stimulator when administered intranasally[reference:3]. Plasma growth hormone concentrations increase dose-dependently after injection of the peptide, peaking at about 30 minutes and then decreasing to baseline values within 240 minutes with a half-life of about 55 minutes in humans<\/p>\n

CD36-Mediated Cardioprotective Effects<\/strong><\/h3>\n

Beyond pituitary GH release, Hexarelin uniquely binds the scavenger receptor CD36, which mediates many of its GH-independent cardioprotective effects including anti-atherosclerotic and anti-ischemic activity[reference:5]. The interaction of Hexarelin with CD36 promotes the transcriptional activation of nuclear receptor PPAR\u03b3 and target gene profiling involved in metabolism. In macrophages, Hexarelin and other GHRPs induce a molecular cascade involving nuclear liver X receptor LXR\u03b1 and expression of apolipoprotein E (apoE) and sterol transporters ABCA1 and ABCG1[reference:6]. Studies have demonstrated that Hexarelin protects rat cardiomyocytes from in vivo ischemia\/reperfusion injury through interleukin-1 signaling pathway<\/p>\n

Neuroprotection<\/strong><\/h3>\n

Hexarelin has also demonstrated neuroprotective effects. Studies have shown that Hexarelin modulation of MAPK and PI3K\/Akt pathways in Neuro-2A cells inhibits hydrogen peroxide-induced apoptotic toxicity.<\/p>\n

Why Is Hexarelin Studied in Switzerland?<\/strong><\/h2>\n

Primarily, researchers study Hexarelin because it represents a well-characterized GHS-R1a agonist with unique CD36-mediated cardioprotective effects, enabling investigation of GH secretion, ghrelin receptor signaling, and cardiovascular protection. In fact, this compound offers a focused tool for studying the molecular mechanisms underlying GH pulsatility, cardiac protection, and neuroendocrine regulation.<\/p>\n

Research has demonstrated Hexarelin’s relevance across multiple domains. Hexarelin has been shown to be a potent GH secretagogue subject to partial feedback inhibition[reference:9]. The peptide has demonstrated GH-releasing activity after oral, intranasal, intravenous, and subcutaneous administration[reference:10]. Studies have examined the neuroendocrine mechanism by which Hexarelin mediates its actions[reference:11].<\/p>\n

Furthermore, Hexarelin has been studied for its potential therapeutic applications in sarcopenia, cachexia, and cardiac conditions[reference:12]. The peptide’s ability to bind both GHS-R1a and CD36 makes it a unique research tool for studying the intersection of growth hormone signaling and cardiovascular protection. Ultimately, researchers who buy Hexarelin 5mg in Switzerland gain access to a comprehensive research tool for investigating GH axis signaling, ghrelin receptor pharmacology, cardioprotective pathways, and neuroprotection.<\/p>\n

Hexarelin Research Areas in Laboratory Studies<\/strong><\/h2>\n\n\n\n\n\n\n\n\n\n\n\n
Research Area<\/th>\nFocus<\/th>\nEvidence Level<\/th>\n<\/tr>\n<\/thead>\n
GHS-R1a Receptor Pharmacology<\/td>\nReceptor binding, Gq\/11 signaling, calcium mobilization, biased agonism<\/td>\nMechanistic \/ In Vitro<\/td>\n<\/tr>\n
GH Secretion<\/td>\nPituitary GH release, GH pulsatility, GH axis regulation<\/td>\nMechanistic \/ In Vivo \/ Clinical<\/td>\n<\/tr>\n
Cardioprotection<\/td>\nCD36-mediated protection, anti-atherosclerotic, anti-ischemic, ischemia-reperfusion<\/td>\nPreclinical<\/td>\n<\/tr>\n
Neuroprotection<\/td>\nMAPK\/PI3K\/Akt pathways, oxidative stress protection, neuronal survival<\/td>\nPreclinical<\/td>\n<\/tr>\n
Metabolic Regulation<\/td>\nPPAR\u03b3 activation, LXR\u03b1 signaling, cholesterol metabolism, ABCA1\/ABCG1<\/td>\nPreclinical<\/td>\n<\/tr>\n
Muscle Wasting<\/td>\nSarcopenia, cachexia, muscle preservation, catabolic states<\/td>\nPreclinical<\/td>\n<\/tr>\n
Hypothalamic-Pituitary Axis<\/td>\nHypothalamic GHRH release, somatostatin modulation, feedback inhibition<\/td>\nPreclinical \/ Clinical<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Hexarelin Compared With Related Research Compounds<\/strong><\/h2>\n\n\n\n\n\n\n\n\n
Compound<\/th>\nResearch Focus<\/th>\nMechanism \/ Target<\/th>\nKey Difference<\/th>\n<\/tr>\n<\/thead>\n
Hexarelin<\/td>\nGH release, cardioprotection, neuroprotection<\/td>\nGHS-R1a agonist (Gq\/11) + CD36 binding<\/td>\nMost potent GH pulse; unique CD36 cardioprotection<\/td>\n<\/tr>\n
GHRP-6<\/td>\nGH release, appetite stimulation<\/td>\nGHS-R1a agonist (Gq\/11 signaling)<\/td>\nStronger appetite stimulation; no CD36 binding<\/td>\n<\/tr>\n
GHRP-2 (Pralmorelin)<\/td>\nGH release, diagnostic testing<\/td>\nGHS-R1a agonist (Gq\/11 signaling)<\/td>\nStronger GH release; less appetite stimulation; no CD36<\/td>\n<\/tr>\n
Ipamorelin<\/td>\nSelective GH release<\/td>\nGHS-R1a agonist (Gq\/11 signaling)<\/td>\nWeaker GH pulse; minimal cortisol\/prolactin elevation; no CD36<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Comparatively, Hexarelin differs from other GHRPs in its unique CD36-mediated cardioprotective effects and potency. On the one hand, Hexarelin is the most potent GH releaser among GHRPs and uniquely binds CD36 for GH-independent cardioprotective effects[reference:13]. On the other hand, GHRP-6 produces notably more appetite stimulation while maintaining similar GH-releasing potency. In contrast, GHRP-2 produces the strongest GH release among GHRPs and has been approved as a diagnostic agent for GH deficiency in Japan, while Ipamorelin provides more selective GH release with minimal cortisol elevation.<\/p>\n

Research Applications for Hexarelin in Switzerland<\/strong><\/h2>\n

Scientists have investigated Hexarelin across several research domains:<\/p>\n